Earnings Call
Jul 29, 2026
Q2 FY2026
EPS Estimate
2.94
EPS Actual
3.60
Post-Earnings Close
$209.23
Earnings Reaction
+1.8%
Biogen's second quarter 2026 results mark a meaningful inflection point in the company's multi-year portfolio transformation, with total revenue of $2.7 billion rising 3% year-over-year and the growth product portfolio crossing a symbolic threshold, for the first time, growth products now generate more revenue than the legacy MS franchise. Core pharmaceutical revenue of $1.8 billion grew 4% year-over-year and 12% sequentially, with the growth portfolio alone up 24% year-over-year to over $1 billion. The quarter's headline story, however, is less about the numbers themselves and more about the structural shift they represent: Biogen is no longer a company managing decline, but one with credible near-term catalysts, a diversified commercial base, and a late-stage pipeline that could reshape the earnings trajectory through the end of the decade.
Report generated on Jul 29, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full BIIB analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.